A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT00730158 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

DRUG: KD018
DRUG: Irinotecan
DRUG: Placebo

Sponsor

Edward Chu, MD

Collaborators

[object Object]